Related Experiment Video
Updated: Dec 4, 2025
08:41
Novel In Vivo Micro-Computed Tomography Imaging Techniques for Assessing the Progression of Non-Alcoholic Fatty Liver Disease
Published on: March 24, 2023
1.5K
Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy
Christopher F Rose1, Piero Amodio2, Jasmohan S Bajaj3
1Hepato-Neuro Laboratory, CRCHUM, Université de Montréal, Montreal, Canada.
Journal of Hepatology
|October 24, 2020
Summary
Hepatic encephalopathy (HE) is a serious liver disease complication causing neuropsychiatric issues. This review covers HE classification, causes, and current and novel treatments for better patient outcomes.
Area of Science:
- Hepatology
- Neurology
- Clinical Medicine
Background:
- Hepatic encephalopathy (HE) is a frequent, serious complication of chronic liver disease and acute liver failure.
- HE presents a spectrum of neuropsychiatric abnormalities, from mild cognitive impairment to coma.
- The condition significantly impacts quality of life, morbidity, and mortality.
Purpose of the Study:
- To critically review the latest classification of hepatic encephalopathy.
- To discuss the pathogenesis and pathophysiological pathways of neurological decline in end-stage liver disease.
- To explore current and novel management and therapeutic strategies for HE.
Main Methods:
- Literature review of recent studies on hepatic encephalopathy.
- Critical analysis of existing data on HE classification and pathogenesis.
- Synthesis of information on diagnostic approaches and treatment options.
Main Results:
- The review provides an updated classification of HE.
- Key pathophysiological mechanisms underlying neurological impairment are detailed.
- Current and emerging therapeutic strategies are evaluated.
Conclusions:
- Hepatic encephalopathy poses a significant clinical and economic burden.
- Understanding pathogenesis is crucial for effective management.
- Novel treatment strategies offer promise for improving patient outcomes.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
100
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
100
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
122
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
122
01:28Esophageal Varices-II: Clinical Features and Management
265
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
265
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug
117
In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
117
01:26Alzheimer's Disease: Overview
1.4K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.4K
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
1.6K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
1.6K